BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• BioMidwest

  Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options

  CSL Behring announced survey results showing that the majority of surveyed people living with chronic inflammatory demyelinating polyneuropathy agree they are interested in exploring more convenient treatment options and that administering treatment at home is extremely/very important to them.

  January 16, 2024

   · 

  9 min read
• BioCapital

  Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

  Precigen, Inc. (Nasdaq: PGEN) today announced that the European Commission (EC) has granted Orphan Drug Designation for the Company’s first-in-class investigational medicine PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP).

  January 16, 2024

   · 

  7 min read
• BioCapital

  Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

  Charles River Laboratories International, Inc. announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus -based gene therapy programs.

  January 16, 2024

   · 

  4 min read